Loading organizations...
Key people at HEDA Ventures.
HEDA Ventures operates as an early-stage venture capital firm, strategically investing in companies developing breakthroughs across the biotech, healthcare, and TMT (Technology, Media, and Telecom) industries. The firm leverages its global network and local expertise, providing portfolio companies with strategic guidance and access to critical resources to navigate complex market landscapes and accelerate their development. This approach underscores a commitment to fostering innovation from its nascent stages.
The firm was established in 2008, founded on the insight that early-stage ventures in specific high-growth sectors could significantly benefit from experienced financial and strategic partners. While precise founding narratives are not extensively detailed, individuals like Lin Xie, a Managing Partner, lead the firm. The founding team’s pedigree includes substantial prior experience in venture capital investment and operations, forming a foundation built on seasoned industry expertise and a deep understanding of startup ecosystems.
HEDA Ventures primarily backs early-stage entrepreneurs, supporting their business expansion by identifying and facilitating access to global market opportunities. The firm’s vision is to accelerate disruptive innovations and emerging trends within its focus sectors, guiding its portfolio companies toward successful market penetration and sustained, impactful growth. It strives to empower these ventures to realize their full potential and achieve lasting market presence.
HEDA Ventures has 3 tracked investments across 3 companies. The latest tracked deal is $50.0M Series B in LYNK Pharmaceuticals in August 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 29, 2021 | LYNK Pharmaceuticals | $50.0M Series B | Lilly Asia Ventures | Legend Capital, MED Fine Capital, NEW Alliance Capital |
| Sep 12, 2017 | Paragon Genomics, Inc. | $8.0M Series A | Co WIN Ventures, Fosun 复星 | Wisemont Capital |
| May 22, 2017 | Symic Biomedical | $30.0M Series B | — | — |
Key people at HEDA Ventures.